Skip to main navigation
  • About
    • Overview
    • Mission & Vision
    • Operating Principles
    • Management
    • Board of Directors
  • Science
    • Overview
    • Therapeutic Areas
    • Therapeutic Platforms
    • Technology Platforms
    • Publications
  • Pipeline
    • Overview
    • Precigen Pipeline
    • Expanded Access Policy
  • Subsidiaries
    • Overview
    • Precigen Actobio
    • Precigen Exemplar
  • Careers
    • Overview
    • Job Postings
    • Postdoc Program
    • Benefits
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock
    • Financials
    • Governance
    • Resources
  • Contact
    • Contact
    • Locations
  • About
    • Overview
    • Mission & Vision
    • Operating Principles
    • Management
    • Board of Directors
  • Science
    • Overview
    • Therapeutic Areas
    • Therapeutic Platforms
    • Technology Platforms
    • Publications
  • Pipeline
    • Overview
    • Precigen Pipeline
    • Expanded Access Policy
  • Subsidiaries
    • Overview
    • Precigen Actobio
    • Precigen Exemplar
  • Careers
    • Overview
    • Job Postings
    • Postdoc Program
    • Benefits
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock
    • Financials
    • Governance
    • Resources
  • Contact
    • Contact
    • Locations
PRECIGEN Investors

Press Releases

IR Nav

  • Press Releases
  • Events & Presentations
  • Stock
  • Financials
  • Governance
  • Resources

Press Releases

Jan 27, 2023
Precigen Announces Closing of Public Offering of Common Stock
Learn More
Jan 24, 2023
Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock
Learn More
Jan 24, 2023
Precigen Announces Proposed $75.0 Million Public Offering of Common Stock
Learn More
Jan 24, 2023
Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis
Learn More
Jan 11, 2023
Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference
Learn More
Jan 04, 2023
Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Respiratory Papillomatosis
Learn More

Upcoming Events

More events are coming soon.

Media Kit

Precigen maintains a media kit with our corporate logo and our CEO’s headshot and bio that can be used by media for editorial purposes. Should you have any questions or seek assets not included in our media kit, please contact:

press@precigen.com

Download
Media Kit
Download
Advancing Medicine with precision™
  • About
    • Overview
    • Mission & Vision
    • Operating Principles
    • Management
    • Board of Directors
  • Science
    • Overview
    • Therapeutic Areas
    • Therapeutic Platforms
    • Technology Platforms
    • Publications
  • Pipeline
    • Overview
    • Precigen Pipeline
    • Expanded Access Policy
  • Subsidiaries
    • Overview
    • Precigen Actobio
    • Precigen Exemplar
  • Careers
    • Overview
    • Job Postings
    • Postdoc Program
    • Benefits
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock
    • Financials
    • Governance
    • Resources
  • Contact
    • Contact
    • Locations

Headquarters

Precigen, Inc.
20358 Seneca Meadows Parkway
Germantown, MD 20876

Connect

  • linkedin
  • twitter
  • youtube

Privacy and Legal Menu

  • Privacy Policy
  • Legal Notices

Copyright

© Precigen. All Rights Reserved.